1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades neurodegenerativas: mecanismos patogénicos

Enfermedades neurodegenerativas: mecanismos patogénicos

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Díaz-Alonso J, de Salas-Quiroga A, Paraíso-Luna J, García-Rincón D, Garcez PP, Parsons M, Andradas C, Sánchez C, Guillemot F, Guzmán M, Galve-Roperh I.

    Loss of Cannabinoid CB1 Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility.

    CEREBRAL CORTEX . 27(11): 5303-5317. Nº de citas: 17

    [doi:10.1093/cercor/bhw309]

  • Bravo-Ferrer I, Cuartero MI, Zarruk JG, Pradillo JM, Hurtado O, Romera VG, Díaz-Alonso J, García-Segura JM, Guzmán M, Lizasoain I, Galve-Roperh I, Moro MA.

    Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.

    Stroke . 48(1): 204-212. Nº de citas: 35

    [doi:10.1161/STROKEAHA.116.014793]

  • Hernández-Tiedra S, Fabriàs G, Dávila D, Salanueva ÍJ, Casas J, Montes LR, Antón Z, García-Taboada E, Salazar-Roa M, Lorente M, Nylandsted J, Armstrong J, López-Valero I, McKee CS, Serrano-Puebla A, García-López R, González-Martínez J, Abad JL, Hanada K, Boya P, Goñi F, Guzmán M, Lovat P, Jäättelä M, Alonso A, Velasco G.

    Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization

    Autophagy . 12(11): 2213-2229. Nº de citas: 82

    [doi:10.1080/15548627.2016.1213927]

  • Bellocchio L, Ruiz-Calvo A, Chiarlone A, Cabanas M, Resel E, Cazalets JR, Blázquez C, Cho YH, Galve-Roperh I, Guzmán M.

    Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK.

    JOURNAL OF NEUROSCIENCE . 36(41): 10611-10624. Nº de citas: 9

    [doi:10.1523/JNEUROSCI.1192-16.2016]

  • Chiarlone A, Börner C, Martín-Gómez L, Jiménez-González A, García-Concejo A, García-Bermejo ML, Lorente M, Blázquez C, García-Taboada E, de Haro A, Martella E, Höllt V, Rodríguez R, Galve-Roperh I, Kraus J, Guzmán M.

    MicroRNA let-7d is a target of cannabinoid CB1 receptor and controls cannabinoid signaling.

    Neuropharmacology . 108: 345-352. Nº de citas: 17

    [doi:10.1016/j.neuropharm.2016.05.007]

  • Andradas C, Blasco-Benito S, Castillo-Lluva S, Dillenburg-Pilla P, Diez-Alarcia R, Juanes-García A, García-Taboada E, Hernando-Llorente R, Soriano J, Hamann S, Wenners A, Alkatout I, Klapper W, Rocken C, Bauer M, Arnold N, Quintanilla M, Megías D, Vicente-Manzanares M, Urigüen L, Gutkind JS, Guzmán M, Pérez-Gómez E, Sánchez C.

    Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

    Oncotarget . 7(30): 47565-47575. Nº de citas: 32

    [doi:10.18632/oncotarget.10206]

  • Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E.

    VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

    SCIENTIFIC REPORTS . 6: 29789-29789. Nº de citas: 44

    [doi:10.1038/srep29789]

  • López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

    A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

    JOURNAL OF NEUROLOGY . 263(7): 1390-1400. Nº de citas: 69

    [doi:10.1007/s00415-016-8145-9]

  • Velasco G, Sánchez C, Guzmán M.

    Anticancer mechanisms of cannabinoids.

    Current Oncology . 23(2): 23-32. Nº de citas: 128

    [doi:10.3747/co.23.3080]

  • de Salas-Quiroga A, Díaz-Alonso J, García-Rincón D, Remmers F, Vega D, Gómez-Cañas M, Lutz B, Guzmán M, Galve-Roperh I.

    Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 112(44): 13693-13698. Nº de citas: 76

    [doi:10.1073/pnas.1514962112]

  • Busquets-Garcia A, Desprez T, Metna-Laurent M, Bellocchio L, Marsicano G, Soria-Gomez E.

    Dissecting the cannabinergic control of behavior: The where matters

    Bioessays . 37(11): 1215-1225. Nº de citas: 54

    [doi:10.1002/bies.201500046]

  • Blázquez C, Chiarlone A, Bellocchio L, Resel E, Pruunsild P, García-Rincón D, Sendtner M, Timmusk T, Lutz B, Galve-Roperh I, Guzmán M.

    The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

    CELL DEATH AND DIFFERENTIATION . 22(10): 1618-1629. Nº de citas: 86

    [doi:10.1038/cdd.2015.11]

  • Díaz-Alonso J, Aguado T, de Salas-Quiroga A, Ortega Z, Guzmán M, Galve-Roperh I.

    CB1 Cannabinoid Receptor-Dependent Activation of mTORC1/Pax6 Signaling Drives Tbr2 Expression and Basal Progenitor Expansion in the Developing Mouse Cortex

    CEREBRAL CORTEX . 25(9): 2395-2408. Nº de citas: 16

    [doi:10.1093/cercor/bhu039]

  • Martín R, Bajo-Grañeras R, Moratalla R, Perea G, Araque A.

    Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways

    Science . 349(6249): 730-734. Nº de citas: 174

    [doi:10.1126/science.aaa7945]

  • Salazar M, Lorente M, García-Taboada E, Gómez EP, Dávila D, Zúñiga-García P, Flores JM, Rodríguez A, Hegedus Z, Mosén-Ansorena D, Aransay AM, Hernández-Tiedra S, López-Valero I, Quintanilla M, Sánchez C, Iovanna JL, Dusetti N, Guzmán M, Francis SE, Carracedo A, Kiss-Toth E, Velasco G.

    TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling.

    Molecular & cellular oncology . 2(3): . Nº de citas: 16

    [doi:10.4161/23723556.2014.980134]

  • Sanchez D, Bajo-Grañeras R, Del Caño-Espinel M, Garcia-Centeno R, Garcia-Mateo N, Pascua-Maestro R, Ganfornina MD.

    Aging without Apolipoprotein D: Molecular and cellular modifications in the hippocampus and cortex

    EXPERIMENTAL GERONTOLOGY . 67: 19-47. Nº de citas: 24

    [doi:10.1016/j.exger.2015.04.003]

  • Stern CA, Gazarini L, Vanvossen AC, Zuardi AW, Galve-Roperh I, Guimaraes FS, Takahashi RN, Bertoglio LJ.

    Delta(9)-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption

    EUROPEAN NEUROPSYCHOPHARMACOLOGY . 25(6): 958-965. Nº de citas: 42

    [doi:10.1016/j.euroneuro.2015.02.001]

  • Abrams DI, Guzman M.

    Cannabis in Cancer Care

    CLINICAL PHARMACOLOGY & THERAPEUTICS . 97(6): 575-586. Nº de citas: 111

    [doi:10.1002/cpt.108]